Statistics

Total Visits

Views
Phase II Trial of Erlotinib plus Capecitabine as First-line Treatment for Metastatic Pancreatic Cancer (XELTA Study)10

Select a period of time:

Number of views in the range

Views
Phase II Trial of Erlotinib plus Capecitabine as First-line Treatment for Metastatic Pancreatic Cancer (XELTA Study)8

Views

Views
November 20231
December 20231
January 20243
February 20240
March 20240
April 20240
May 20243
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States7
Spain1
 

Top cities views

Views
Chicago2
Boardman2
Ashburn1
Bertamirans1